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Post-Traumatic Stress Disorder: Basic Science and Clinical
Practice is an edited volume on a topic of great interest to the
lay public, clinicians, and research scientists. Because many of
the readers of Neuron may not be familiar with posttraumatic
stress disorder (PTSD), it seems propitious to first describe this
all too common psychiatric disorder. PTSD is the only syndrome
in the entire Diagnostic and Statistical Manual–IV (DSM-IV),
published by the American Psychiatric Association, that occurs
as a consequence of exposure to a stressor, namely a traumatic
event. The traumatic event that the person experienced or
witnessed must have involved actual or threatened death or
injury, or threat to physical injury of oneself or others, and the
person must have responded with intense fear, helplessness,
or horror. In addition, patients experience three additional major
symptom clusters including re-experiencing, avoidance or
numbing, and increased arousal. Re-experiencing (requires
one or more symptoms) includes recurrent intrusive recollec-
tions of the traumatic event, nightmares, flashbacks, and both
psychological and physiological distress upon exposure to the
trauma or related stimuli. Avoidance and numbing (requires three
or more symptoms) include avoidance of thoughts, feelings,
conversations, activities, places, and people associated with
the trauma, as well as amnesia, diminished interest in activities,
detachment or estrangement from others, restricted range of
affect, and the sense of a limited future. Increased arousal
(requires two or more symptoms) includes sleep disturbances,
irritability and anger outbursts, difficulty concentrating, hypervi-
gilence, and being easily startled. In order to fulfill DSM-IV criteria
for PTSD, patients must exhibit symptoms from each of the
aforementioned categories, which cause significant distress or
impairment and persist for at least one month. In addition, of
all the major psychiatric syndromes, PTSD exhibits the highest
rate of comorbidity with other disorders, most notably major
depression, other anxiety disorders, substance abuse, and a
variety of medical disorders.
Although PTSD was first recognized as a consequence of
experiences that occurred during military combat, it has now
appropriately been expanded to responses to a variety of
traumatic events, including natural disasters, rape, automobile
and airplane accidents, and terrorism, to name a few. Indeed,
although PTSD was once considered a relatively rare condition,426 Neuron 63, August 27, 2009 ª2009 Elsevier Inc.it is now known to be one of the most prevalent of all psychiatric
conditions, with a lifetime prevalence rate in the United States of
almost 8%. Women have twice the prevalence rate of PTSD
(10.4%) compared to men (5%).
Unfortunately, the increasing involvement of a variety of coun-
tries, including the United States, in wars in the last decade,
coupled with a number of national and man-made disasters,
have led to a marked increase in the presentation of veterans
and civilians with PTSD. In view of the increasing public health
burden associated with PTSD, the burgeoning tools of neurosci-
ence have been increasingly applied to understanding this
disorder, as has the desire to uncover new and effective treat-
ments. This concatenation of events, namely, the increasing
magnitude of the public health burden of PTSD, the importance
of understanding its pathophysiology, and the wish to entice
both basic and clinical investigators into this research arena,
renders the appearance of this volume on PTSD timely. Of the
three editors, Keane and LeDoux are well known in the PTSD/
neurobiology of stress domain. Keane has been on the forefront
of clinical investigation and clinical service delivery of United
States service veterans with PTSD and has worked closely with
Matt Friedman, Director of the National Center for PTSD. LeDoux
is oneof the foremost basic neuroscientists in the neurobiology of
fear and emotion. The third editor, Shiromani, has focused on the
neurobiology of sleep, a long-neglected area in PTSD specifically
and anxiety disorders in general. The volume is organized into six
sections comprised of two to four chapters each after an intro-
ductory chapter by Keane and colleagues on Definition, Preva-
lence, and Risk Factors. This opening chapter is a particularly
useful review for the neophyte, covering not only diagnostic
criteria (a table with the DSM-IV criteria would have been helpful)
but epidemiology and risk factors as well. It might have been
helpful to include information on one or more of the dimensional
rating scales used to measure symptom severity in PTSD, such
as the Clinical Administered PTSD Scales (CAPS). Other impor-
tant points worth highlighting would include the high risk of sui-
cide by this population, the difficulty of studying homogeneous
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atric and medical comorbidity, the burgeoning database on the
presence of child abuse and neglect as a major risk factor, and
the candidate gene approach in searching for biologic risk
factors. Admittedly, I am somewhat biased toward the latter
two areas in view of our own group’s contributions in this regard
(Binder et al., 2008). In addition, becausemany of the readers will
not be familiar with the clinical presentation of PTSD, a few illus-
trative case vignettes would have been quite informative.
The remaining sections of the book focus on the Amygdala
and Fear, Animal Models of PTSD, PTSD and Arousal, Stress
Hormones in PTSD, and Treatment Strategies. There is much
to be learned in the 17 chapters that comprise these sections.
In the spirit of full disclosure, two of the chapters are authored
by a few of my faculty colleagues at Emory: Rainnie and Ressler
on the Physiology of the Amygdala and Rothbaum on Virtual
Reality Therapy.
The review of the Amygdala and the Neural Pathways of Fear
by Debiec and LeDoux is comprehensive, yet succinct; its major
shortcoming is the poor quality of the fMRI figure, which needed
both to be printed in color and included with the other color
plates and to have far better resolution. Rainnie and Ressler,
my Emory colleagues, review the Physiology of the Amygdala,
and their contribution focusing on electrophysiology and neuro-
chemistry is complementary to the previous chapter. Fischer and
Tsai contribute a solid review of molecular pathways implicated
in the reduction of fear, and the last chapter in this section by
Verfaillie and Vasterlin focuses on Memory in PTSD. This is
a very solid contribution that outlines a number of the controver-
sies in the field, appropriately highlighting memory changes as
central to the syndrome. The next section comprised of two
chapters is centered on Animal Models of PTSD. The two chap-
ters are quite complementary, the first by Cohen and Richter-
Levin focusing on rodent behavioral models with the second
by Rao and colleagues focusing more on synaptic plasticity,
electrophysiology, and molecular mechanisms. In contrast to
the animal models of other major psychiatric disorders, there
was no discussion of non-human primatemodels, a commentary
on a clear lacune in the field.
The next section is comprised of four chapters on PTSD and
arousal. The first chapter by the lead editor and a colleague
provides a review of Arousal Neurons in the Brain, which focuses
on sleep physiology. Carter andDeLecea next review a burgeon-
ing area—the hypocretins, neuopeptides that have emerged
as prime modulators of arousal, in part due to their extensive
interactions with corticotropin-releasing factor (CRF) circuits.
Berridge elegantly reviews the seminal role of the locus coeru-
leus-norepinephrine system in stress, followed by Sanford and
Tang’s integrative discussion of The Effect of Stress on Sleep
and its Relationship to PTSD.
The following section on Stress Hormones has two contribu-
tions. The first is authored by Yehuda, arguably the leader of
this field. Because the subject matter intersects with my own
research area and the author is quite critical of our hypotheses,
it is not surprising that I would feel compelled to respond. Her
major point of contention with our work appears to be our view
that HPA axis hypoactivity in PTSD is characterized by CRF
hypersecretion that eventually results in CRF receptor downregu-lation in the anterior pituitary and cortisol hyposecretion. Two
major points are relevant here—first, although she appropriately
focuses on epigenetic mechanisms, nowhere does she consider
the importance of functional genetic polymorphisms as for
example our group studies of the GC cochaperone protein,
FKBPS (Binder et al., 2008). Moreover, Yehuda does not distin-
guish between extrahypothalamic and hypothalamic hyperac-
tivity of CRF circuits; it is the former that likely contributes to the
elevations in CSF CRF concentration in PTSD patients, as well
as many of the anxiety symptoms characteristic of the disorder.
In spite of my disagreement on interpretation of some of the
extantfindings, thischapter isascholarly treatiseofacomplicated
area, undoubtedly central to the pathophysiology of PTSD.
Miller and colleagues follow with a discussion of low plasma
cortisol concentrations and exaggerated startle responses as
biomarkers, appropriately emphasizing on individual differences
andcomorbidities. Thenext section is comprisedof his twochap-
ters on Brain Imaging in PTSD. Surprisingly, there is no additional
chapter summarizing the myriad of structural brain imaging
studies in this section, particularly those that have focused on
the hippocampus. Liberzon, a leader in PTSD, and his colleague
Garfunkel review functional imaging, and the result is a tour de
force. This is a very difficult and contradictory literature, and the
authors do a superb job in making sense of it for the new reader.
The following chapter by Shin appears to be somewhat of a post-
script to the previous chapter because it is somewhat redundant
with material covered elsewhere in the volume and many of her
studies are reviewed in the previous chapter.
The final section of this volume is on Treatment Strategies. The
first chapter by Raskind, a leading psychopharmacologist, is
a true gem, particularly for those unfamiliar with the field. He
comprehensively describes all of the relevant data on Pharma-
cologic Treatments of PTSD using a well thought out outline
for each drug. He first describes the neurobiological rationale
for its use in PTSD, followed by a careful review of the clinical trial
data. The review is remarkably up to date, including the contro-
versy surrounding the Institute of Medicine report (Institute of
Medicine, 2008), which in contrast with the U.S. Food and
Drug Administration concluded that the current data did not
support the efficacy of any psychopharmacological agent in
the treatment of PTSD. The two chapters that follow by Strass
et al. and Rizzo et al. summarize, respectively, Guided Imagery
and Virtual Reality Exposure Therapy in PTSD. The former
chapter documents very promising results in a preliminary study.
The latter provides an authoritative review on the efficacy of
exposure therapy in PTSD, endorsed by the IOM, coupled with
the use of virtual reality techniques. The color photographs
document how realistic virtual reality technology truly is.
Overall, this book is to be recommended, particularly to neuro-
biology and psychology graduate students and fellows, psychi-
atry residents, and faculty who want a ‘‘crash course’’ in PTSD. It
is not encyclopedic but that was not the goal of its editors. Many
leaders in the field did not contribute to this relatively slim
volume, but the majority of those who did are outstanding. There
are several other volumes and journal supplements on PTSD
available, which readers of Neuron would find complementary
to this new entry to the field: Risk Factors for Posttraumatic
Stress Disorder, edited by Rachel Yehuda, Ph.D. (Yehuda,Neuron 63, August 27, 2009 ª2009 Elsevier Inc. 427
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Book Review1999); Psychobiology of Posttraumatic Stress Disorder, editors:
Rachel Yeduda and Alexander C. McFarlane (Yehuda and
McFarlane, 1997); and CNS Spectrums Academic Supplement
The Cape Town Consensus on Posttraumatic Stress Disorder,
edited by D.J. Stein and J. Zohar (Stein et al., 2009).
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